Natera, Inc. (NASDAQ:NTRA) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its position in shares of Natera, Inc. (NASDAQ:NTRA) by 19.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 115,965 shares of the medical research company’s stock after selling 27,938 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Natera were worth $18,357,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc grew its stake in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. raised its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 59 shares during the period. Finally, True Wealth Design LLC acquired a new position in shares of Natera during the 3rd quarter valued at $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NTRA opened at $151.15 on Friday. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The firm has a market capitalization of $20.43 billion, a PE ratio of -85.88 and a beta of 1.80. The firm has a 50-day moving average price of $161.23 and a 200 day moving average price of $149.50. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Robert W. Baird raised their price objective on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Piper Sandler boosted their price target on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research report on Friday, February 28th. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group raised their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus target price of $178.12.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 87,272 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now directly owns 203,354 shares in the company, valued at approximately $29,160,963.60. The trade was a 30.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 1,026 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.04, for a total transaction of $149,837.04. Following the transaction, the insider now owns 144,782 shares of the company’s stock, valued at approximately $21,143,963.28. This trade represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 307,466 shares of company stock valued at $49,047,655. Corporate insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.